Provided by Tiger Fintech (Singapore) Pte. Ltd.

VistaGen Therapeutics

2.36
+0.15006.79%
Post-market: 2.370.0100+0.42%19:41 EDT
Volume:155.57K
Turnover:360.07K
Market Cap:68.11M
PE:-1.53
High:2.38
Open:2.23
Low:2.19
Close:2.21
Loading ...

Vistagen Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Reuters
·
07 Feb

Press Release: Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Dow Jones
·
06 Feb

Vistagen granted USPTO patent for AV-101 to treat neuropathic pain

TIPRANKS
·
05 Feb

BRIEF-Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Reuters
·
05 Feb

Vistagen Receives U.S. Patent for Av-101 to Treat Neuropathic Pain

THOMSON REUTERS
·
05 Feb

Vistagen Therapeutics Inc - Patent Will Not Expire Until at Least 2034

THOMSON REUTERS
·
05 Feb

Vistagen Therapeutics-Plans to Seek Potential Strategic Collaborations to Further Advance Potential Clinical Development, Commercialization of Av-101

THOMSON REUTERS
·
05 Feb

BRIEF-Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Reuters
·
14 Jan

Vistagen Therapeutics Inc - Phase 2a Study Evaluates Efficacy, Safety, and Tolerability of Ph284

THOMSON REUTERS
·
14 Jan

Vistagen Announces Positive Results From Exploratory Phase 2a Study of Ph284 in Cancer Cachexia

THOMSON REUTERS
·
14 Jan

Vistagen Therapeutics Inc - Ph284 Demonstrates No Serious Adverse Events

THOMSON REUTERS
·
14 Jan

BRIEF-Vistagen Initiates Fasedienol Repeat Dose Study For The Acute Treatment Of Social Anxiety Disorder

Reuters
·
10 Jan

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
10 Jan

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Business Wire
·
10 Jan